Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Elena Roveda"'
Autor:
Valentina Trevisan, Marco Zecca, Elena Roveda, Eleonora Bellani, T. Barbagallo, F. Prestinari, Valeria Brazzelli, C. Rona, Franco Locatelli, Giovanni Borroni
Publikováno v:
Pediatric Dermatology. 23:175-178
Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid leukemia. It acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase. It also inhibits both c-kit and platelet-derived growth factor recepto
Autor:
Elena Roveda, Valeria Brazzelli, Michela Castello, F. Prestinari, Giovanni Borroni, Eleonora Bellani, T. Barbagallo
Publikováno v:
Pediatric dermatology. 22(3)
We report our experience with UV-B narrowband (UV-B–NB) therapy in children affected by vitiligo. We studied 10 Caucasian Italian children (six boys, four girls, mean age 9.7 years ± 2.67). Treatment mean term was 5.6 months; frequency was three t
Autor:
Eleonora Bellani, Elena Roveda, Ester Orlandi, Francesco Passamonti, Camilla Vassallo, F. Prestinari, T. Barbagallo, Valeria Brazzelli, Giovanni Borroni
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of an IM-induced pityriasis rosea (PR)-like cutaneous eruption. Patients developed an erythematous, slightly pruritic, macular ski
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20850b143f3e91aa7ccb221ee36c4f7e
http://hdl.handle.net/11383/2023252
http://hdl.handle.net/11383/2023252